



NDA 10-669 / S-028

SmithKlineBeecham d/b/a GlaxoSmithKline
2301 Renaissance Blvd.
P.O. Box 61540
King of Prussia, PA 19406-2772

Attention: Matthew Whitman
Associate Director, Regulatory Affairs

Dear Mr. Whitman:

Please refer to your supplemental new drug application dated August 25, 2003, received August 28, 2003, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Leukeran (chlorambucil) Tablets.

Additionally, we acknowledge receipt of your September 4, 2003 correspondence.

This supplemental new drug application provides for addition of a Geriatric Use subsection under PRECAUTIONS.

We have completed our review of this application and it is approved, effective on the date of this letter, for use as recommended in the agreed upon August 25, 2003 labeling text.

The final printed labeling (FPL) must be identical to the enclosed labeling (text for the package insert, and patient package insert) submitted labeling dated August 25, 2003.

Please submit the FPL electronically according to the guidance for industry titled Providing Regulatory Submissions in Electronic Format – NDA. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated “FPL for approved supplement NDA 10-669 / S-028.” Approval of this submission by FDA is not required before the labeling is used.

If you issue a letter communicating important information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2
FDA
5600 Fishers Lane
Rockville, MD 20857

NDA 10-669 / S-028

Page 2

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Maureen Pelosi, Regulatory Project Manager, at (301) 594-5778.

Sincerely,

Richard Pazdur, M.D.
Director
Division of Oncology Drug Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

Enclosure: labeling

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Richard Pazdur
11/13/03 08:47:15 AM